Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA Needs Mid-Cycle Correction System As Part Of Reauthorization, Industry Says

Executive Summary

Industry wants to place benchmarks in PDUFA that would allow for changes mid-stream, instead of waiting until the end of each five-year cycle.

You may also be interested in...



PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers

Industry and FDA agreed to a recommendation package for the PDUFA V commitment letter after dividing agency proposals into three tiers and funding two.

PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers

Industry and FDA agreed to a recommendation package for the PDUFA V commitment letter after dividing agency proposals into three tiers and funding two.

PDUFA Formula Could Better Incorporate Present Economic Conditions

FDA may give up some consistency in its user fee inflation formula, making it more beholden to the short-term whims of the U.S. economy.

Related Content

Topics

UsernamePublicRestriction

Register

PS053313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel